VTE Prophylaxis — Drug-Class Hub
VTE prophylaxis is the single most important preventable intervention in major pelvic urologic surgery. Radical cystectomy carries the highest VTE risk of any urologic procedure (3–11.6%); major open prostate and kidney reconstruction sit immediately below; over 50% of VTE events occur after hospital discharge at a mean of 15–20 days post-op.[1][2][3][8] All major guidelines recommend pharmacologic prophylaxis for all major abdominopelvic cancer-or-reconstructive surgery and extended prophylaxis (4 weeks) after major abdominopelvic oncology / reconstructive surgery (Grade 1A).[4][5][6]
This article is the drug-class pharmacology hub — agent mechanism, dose, renal / weight / neuraxial caveats, and the evidence that matters for selecting an agent. The workflow — risk-assessment (Caprini) applied to specific GU operations, bridge-or-hold decisions for chronically anticoagulated patients, bleeding-vs-thrombosis weighing at the bedside, and antiplatelet management — lives at Antithrombotic therapy and should not be re-derived here.
For related topics see Anticoagulation reversal and ERAS.
VTE Risk in Urologic Surgery — The Scope
| Procedure | 30-day VTE | Post-discharge share | Notes |
|---|---|---|---|
| Radical cystectomy (open) | 3.16–11.6% | 55–58% | Highest-risk urologic operation[1][2][3] |
| Radical cystectomy (robotic) | 2.6–5.5% | > 50% | Similar post-discharge pattern[7] |
| Open prostatectomy | 0.8–15.7% | 82.6% | Wide range by series[7] |
| Robotic prostatectomy | 0.2–0.9% | > 80% | Baseline risk low[7] |
| Radical nephrectomy (open) | 1.0–4.4% | Variable | OR 3.3 vs RP[7] |
| Partial nephrectomy (MIS) | 0.7–3.9% | Variable | — |
| Nephroureterectomy | ~2.5% | Variable | — |
| TURP | Very low | — | Routine prophylaxis not required[9] |
Multivariable risk factors in major urologic surgery: cystectomy (OR 2.96), blood transfusion (OR 2.29), age ≥ 80 (OR 1.98), BMI ≥ 40 (OR 1.82), CHF (OR 1.75), steroid use (OR 1.55), thrombocytosis (OR 1.43), leukocytosis (OR 1.41).[3]
Mean time to VTE diagnosis after cystectomy-with-diversion: 15.2 days post-op (median 20 days) — well beyond typical discharge. This is the entire rationale for extended prophylaxis.[2][8]
Risk Stratification — The Caprini Score
The Caprini risk-assessment model is the most validated surgical VTE risk-stratification tool.[10] A typical radical cystectomy patient (age > 60 + malignancy + major surgery > 45 min + central venous access) scores ≥ 7 — the threshold at which pharmacologic prophylaxis demonstrably reduces VTE in the Pannucci 2017 meta-analysis (OR 0.60 for scores 7–8; OR 0.41 for scores > 8). Scores ≤ 6 did not benefit from chemoprophylaxis.[12]
| Caprini score | Risk category | VTE incidence w/o prophylaxis | Recommended approach |
|---|---|---|---|
| 0 | Very low | ~ 0.5% | Early ambulation only |
| 1–2 | Low | ~ 1.5% | Mechanical (IPC preferred) |
| 3–4 | Moderate | ~ 3% | Pharmacologic ± IPC |
| ≥ 5 | High | 6–10.7% | Pharmacologic + IPC; consider extended prophylaxis |
1. Enoxaparin (Lovenox) — LMWH First-Line
Most extensively studied agent for surgical VTE prophylaxis in cancer and major reconstructive surgery and the guideline-preferred first-line agent per ITAC and NCCN.[4][5]
Mechanism
LMWH, mean MW ~4,500 Da. Anti-Xa : anti-IIa ratio 14:1 (UFH is 1.2:1) — more targeted, more predictable.[13]
Dosing
| Indication | Dose | Timing | Duration |
|---|---|---|---|
| Abdominopelvic surgical prophylaxis | 40 mg SC once daily | 2 h preop or bedtime preop | 7–10 days inpatient |
| Extended post-discharge prophylaxis | 40 mg SC once daily | Continue from inpatient | 28 days total |
| Severe renal impairment (CrCl < 30) | 30 mg SC once daily | Same | Same |
| BMI ≥ 40 kg/m² | 40 mg SC q12 h or 0.5 mg/kg SC daily | Same | Same |
| Weight < 50 kg | 20 mg SC daily (consider anti-Xa monitoring) | Same | Same |
Source: FDA label + NCCN.[5][13]
Pharmacokinetics
- Bioavailability ~100% SC
- Peak anti-Xa 3–5 h
- Half-life 4.5 h single dose; ~7 h repeated
- Primarily renal elimination — AUC ↑ 65% in severe renal impairment
- Monitor with anti-factor-Xa levels (not aPTT / PT)[13][14]
FDA boxed warning — spinal / epidural hematoma
Epidural / spinal hematoma may occur with LMWH during neuraxial anesthesia or spinal puncture, potentially causing long-term or permanent paralysis. Place / remove neuraxial catheters ≥ 12 h after prophylactic LMWH dose and ≥ 24 h after therapeutic dose. Do not give LMWH for ≥ 4 h after catheter removal.[13]
Extended-prophylaxis evidence
| Source | Finding |
|---|---|
| 2019 meta (18 studies, n = 7,495) | Extended LMWH (4 wk) ↓ symptomatic VTE 2.0% → 1.0% (RR 0.48); no increase in clinically relevant non-major bleeding[4] |
| Earlier meta | Extended prophylaxis ↓ any VTE 5.6% → 2.6% (RR 0.44); ↓ proximal DVT 2.8% → 1.4% (RR 0.46)[15] |
| ITAC 2022 | Grade 1A — extended prophylaxis after major abdominopelvic cancer surgery[4] |
Strengths vs LMWH limitations
Strengths: once-daily dosing, predictable PK, lower HIT risk than UFH (< 1% vs 1–5%).[11][16]
Limitations: SC injection (compliance barrier), renal dose adjustment, ~60% anti-Xa reversal by protamine only, accumulates in renal impairment.[13]
2. Unfractionated Heparin (UFH) — For Severe Renal Impairment
Mechanism
Binds antithrombin III → inhibits thrombin (IIa) and factor Xa in ~1.2:1 ratio — broader but less predictable. Reticuloendothelial clearance — no renal dose adjustment.[13]
Dosing
| Indication | Dose | Timing |
|---|---|---|
| Standard surgical prophylaxis | 5,000 U SC q8 h | 2 h preop + q8 h |
| BMI ≥ 40 kg/m² | 7,500 U SC q8 h | Same |
| Weight < 50 kg | 2,500 U SC q8–12 h | Same |
Strengths vs limitations
Strengths over LMWH:
- No renal dose adjustment — the key advantage, and why UFH is preferred if CrCl < 30
- Fully reversible with protamine (vs ~60% for LMWH)
- Short half-life 1–2 h IV
- Lower cost
- Compatible with neuraxial anesthesia (q12 h dosing)[5]
Limitations:
- TID dosing — compliance / nursing burden
- Higher HIT risk (1–5% vs < 1% for LMWH)[11]
- Less predictable PK; platelet monitoring needed
LMWH is preferred over UFH in NCCN / ITAC / ACCP / ASH guidelines unless contraindicated.[4][5][6]
3. Apixaban (Eliquis) — The Emerging Extended-Prophylaxis Agent
Most important recent change in the urologic VTE landscape: apixaban has become the preferred agent for extended post-discharge prophylaxis in urologic oncology practice — 70% of urologic oncologists now prescribe apixaban (up from 0% in 2019) for extended prophylaxis after radical cystectomy.[17]
Mechanism
Direct, selective, reversible inhibitor of factor Xa (free and prothrombinase-bound). Oral bioavailability ~50%; half-life ~12 h. ~25% renal elimination — better renal tolerance than rivaroxaban.[18]
Dosing
| Setting | Dose | Duration | Caveat |
|---|---|---|---|
| Inpatient surgical prophylaxis | 2.5 mg PO q12 h starting POD 1–7 (bridge with UFH/LMWH until PO safe) | Until discharge | NCCN validated for gyn cancer; off-label for cystectomy |
| Extended post-discharge prophylaxis | 2.5 mg PO q12 h | 28 days | NCCN validated for gyn; widely used off-label for cystectomy |
| Hip / knee replacement (FDA) | 2.5 mg PO q12 h starting 12–24 h postop | 12 d (knee) / 35 d (hip) | FDA-approved |
Source: NCCN + FDA label.[5][18]
Evidence in urologic surgery
Westerman 2022 J Urol — prospective QI at MD Anderson, apixaban vs enoxaparin for extended prophylaxis after abdominopelvic urologic oncology surgery (n = 315):[19]
- Safety events (VTE + major bleed): 0% apixaban vs 3.1% enoxaparin (p = 0.028 for superiority)
- Compliance events: 14.3% apixaban vs 33.5% enoxaparin (p = 0.0001)
- Apixaban met prespecified noninferiority — in fact superior for both safety and compliance
RCT, mixed cancer surgery (n = 400) — apixaban vs enoxaparin: similar major bleed (0.5% both), similar VTE (1.0% vs 1.5%).[4]
Critical caveat for urinary-diversion patients
Apixaban is absorbed in the stomach, proximal small bowel, and colon. Patients who have had significant intestinal resection (ileal conduit, orthotopic neobladder, Indiana pouch using ileocecal segment) may have suboptimal absorption. The concern is theoretical (Westerman 2022 showed excellent safety in cystectomy patients), but flag it in extensive resections or short-bowel physiology.[5]
Renal dosing
Caution if CrCl < 30; the NCCN considers apixaban in HIT patients when no alternative exists.[5]
Neuraxial-anesthesia caveat
Apixaban is contraindicated with indwelling neuraxial catheters — initiate after catheter removal (the Westerman protocol did exactly this).[5]
4. Rivaroxaban (Xarelto) — Limited Role in Urology
NCCN position
Restricted to laparoscopic colorectal cancer surgery for extended prophylaxis — not broadly recommended for urologic diversion.[5]
Dosing (colorectal indication)
- 10 mg PO daily × 21 days, started after 1 week of standard-dose LMWH
- Avoid if CrCl < 30[18]
Differences from apixaban relevant to urology
- Requires LMWH bridging for 1 week first
- ~33% renal clearance (vs 25% apixaban) — more renal-dependence
- Once-daily (vs q12 h for apixaban)
- Less urology-specific evidence
- Same absorption concerns after bowel resection
5. Sequential Compression Devices (IPC / SCD) — Mechanical Prophylaxis
Mechanism
Cyclical external lower-extremity pressure → ↓ venous stasis, ↑ venous flow velocity, stimulates endothelial tPA release → fibrinolysis. Does not increase bleeding risk — the key differentiator from pharmacologic prophylaxis.[16]
Evidence
Kakkos Cochrane 2022 — IPC + pharmacologic vs pharmacologic alone:[20]
- DVT: 34 vs 84 per 1,000 (high-certainty)
- PE: 5 vs 10 per 1,000 (low-certainty)
- No obvious bleeding difference
IPC + pharmacologic vs IPC alone: DVT 18 vs 34 per 1,000; PE 3 vs 6 per 1,000 (low-certainty).[20]
PREVENT 2019 NEJM (critically ill medical patients, n = 2,003) — adding IPC to pharmacologic prophylaxis did not ↓ proximal DVT (HR 0.93) — largely medical-ICU population, limited surgical generalizability.[21]
Guideline positioning
| Guideline | Recommendation |
|---|---|
| NCCN | IPC as adjunct; IPC alone when pharmacologic contraindicated (Category 1)[5] |
| ITAC 2022 | Mechanical not recommended as monotherapy except when pharmacologic contraindicated (Grade 2A)[4] |
| ACCP 2012 | Dual prophylaxis for high-risk patients (Grade 2C)[6][22] |
| ACOG | Dual prophylaxis for high-risk gyn surgery[11] |
Contraindications to mechanical prophylaxis
Absolute: acute DVT (unless on therapeutic anticoagulation), severe arterial insufficiency. Relative: large hematoma, skin ulceration, mild PAD, peripheral neuropathy.[5]
Practical points
- IPC > graduated compression stockings (GCS) — CLOTS trials showed IPC reduced DVT while GCS did not and had higher skin complications.[5]
- Target ≥ 18 h daily IPC wear; use portable battery-powered devices that record wear time.[22]
- Ambulation is not adequate VTE prophylaxis — efficacy and required "dose" unknown; don't substitute for formal prophylaxis.[16]
Contraindications to Pharmacologic Prophylaxis
Per NCCN:[5]
Absolute:
- Active bleeding
- Thrombocytopenia (platelets < 40–50 × 10⁹/L)
- INR > 1.5 (without warfarin for target)
- Current / previous HIT (contraindicates LMWH and UFH)
- Pork allergy (LMWH / UFH)
When pharmacologic prophylaxis is contraindicated: IPC monotherapy, and add pharmacologic prophylaxis as soon as contraindication resolves.[4][5]
Guideline Comparison — Extended Prophylaxis
All major guidelines recommend 4-week extended prophylaxis after high-risk abdominopelvic oncology / reconstructive surgery:
| Guideline | Recommendation | Grade | Agent preference |
|---|---|---|---|
| NCCN 2025 | Extended prophylaxis up to 4 weeks for high-risk abdominopelvic cancer surgery | Category 2A | LMWH preferred; apixaban (gyn only), rivaroxaban (colorectal only)[5] |
| ITAC 2022 | Extended LMWH 4 weeks after major cancer abdominopelvic surgery | Grade 1A | LMWH; DOACs insufficient (Grade 2B)[4] |
| ASCO 2020 | Extended LMWH 4 wk for high-risk (restricted mobility, obesity, prior VTE) | Strong | LMWH |
| ACCP 2012 | Extended LMWH for cancer patients undergoing major abdominopelvic surgery | Grade 1B | LMWH[6] |
| ASH 2019 | Against pharmacologic prophylaxis for TURP; LMWH or UFH if used | Conditional | LMWH or UFH[9] |
2023 SUO survey — practice patterns after radical cystectomy[17]
- 98% use extended prophylaxis (up from 80% in 2019)
- 70% use apixaban (up from 0% in 2019) — the fastest-changing practice pattern in perioperative urology
- 28% use enoxaparin; 2% use other
Procedure-Specific Recommendations (Urology)
| Procedure | Inpatient | Extended (4 wk) | Mechanical |
|---|---|---|---|
| Cystectomy with diversion (open or robotic) | Enoxaparin 40 mg SC daily (start 2 h preop) or UFH 5,000 U SC q8 h + IPC | Apixaban 2.5 mg PO q12 h × 28 d or enoxaparin 40 mg SC daily × 28 d | IPC intraop + postop |
| Open radical prostatectomy | Enoxaparin 40 mg SC daily + IPC | Consider 4 wk (high VTE risk) | IPC |
| Robotic prostatectomy (RALP) | Enoxaparin 40 mg SC daily + IPC | Consider in high-risk (~30% use EP) | IPC |
| Radical / partial nephrectomy | Enoxaparin 40 mg SC daily + IPC | Consider in high-risk | IPC |
| RPLND | Enoxaparin 40 mg SC daily + IPC | Consider (~30% use EP) | IPC |
| TURP | Not routine per ASH | Not indicated | Consider IPC[9] |
Sources: NCCN + ITAC + SUO 2023 survey.[4][5][17]
Special Considerations in Reconstructive Urology
Renal impairment after diversion
Cystectomy-with-diversion patients frequently have baseline renal impairment (post-obstructive, post-chemo, solitary kidney). Agent selection matters:[5]
| Agent | CrCl 30–50 | CrCl < 30 |
|---|---|---|
| Enoxaparin | Standard 40 mg SC daily | 30 mg SC daily |
| UFH | No adjustment | No adjustment — preferred |
| Apixaban | 2.5 mg q12 h | Caution |
| Rivaroxaban | Caution | Avoid |
Absorption after bowel resection (apixaban / rivaroxaban)
NCCN flags suboptimal DOAC absorption after extensive intestinal resection.[5] The concern is theoretical — Westerman's apixaban data in cystectomy patients are reassuring — but worth considering in patients with extensive bowel resection or short-bowel physiology.[19]
Neuraxial anesthesia
Many cystectomy patients receive epidural analgesia. Timing matters:[5][10]
| Agent | Catheter placement / removal |
|---|---|
| Enoxaparin 40 mg daily | Place / remove ≥ 12 h after last dose; next dose ≥ 4 h after removal |
| UFH 5,000 U q12 h | Compatible with neuraxial |
| Apixaban | Contraindicated with indwelling catheters; initiate after removal |
Cross-Reference — What Lives on the Workflow Page
To avoid duplication, the following sit on Antithrombotic therapy:
| Topic | Page |
|---|---|
| Procedure-specific Caprini application in urology | Workflow |
| Bridge-or-hold decisions for chronically anticoagulated patients | Workflow |
| Antiplatelet management around pelvic surgery | Workflow |
| Antithrombin concentrate for heparin resistance | Workflow |
| Drug-class pharmacology of each prophylaxis agent | This article |
| Extended-prophylaxis evidence base | This article |
| Apixaban-after-bowel-resection absorption caveat | This article |
Practical Pearls
- Extended VTE prophylaxis (4 weeks) after cystectomy-with-diversion is now standard of care. Adoption has risen 80% → 98% among urologic oncologists since 2019.[1][4][17]
- Apixaban 2.5 mg PO q12 h has become the preferred extended-prophylaxis agent after reconstructive pelvic surgery — 70% of SUO members now use it. Driver: dramatic compliance improvement (14.3% vs 33.5% compliance events) and noninferior-to-superior safety vs enoxaparin.[17][19]
- LMWH remains guideline-preferred first-line per ITAC (Grade 1A) and NCCN. DOACs have insufficient evidence for a formal recommendation outside the gyn (apixaban) and colorectal (rivaroxaban) indications — off-label use in cystectomy is widespread but not yet guideline-endorsed.[4][5]
- UFH is preferred in severe renal impairment (CrCl < 30) — no dose adjustment, fully protamine-reversible.[5]
- Dual prophylaxis (pharmacologic + IPC) for high-risk cancer surgery. IPC alone when pharmacologic contraindicated.[4][5][20]
- Caprini ≥ 7 is the threshold where chemoprophylaxis demonstrably benefits — and a typical cystectomy patient scores ≥ 7 by default.[12]
- > 50% of VTE events after cystectomy occur post-discharge at mean day 15–20. This is why inpatient-only prophylaxis fails.[2][8]
- Flag bowel-resection absorption when prescribing apixaban / rivaroxaban post-diversion — theoretical concern, reassuring real-world data.[5][19]
- Timing of enoxaparin around neuraxial catheters: place / remove ≥ 12 h after last prophylactic dose; next dose ≥ 4 h after removal.[13]
- TURP does not need pharmacologic prophylaxis unless additional risk factors.[9]
Related Articles
- Antithrombotic therapy — companion workflow article (Caprini-in-urology, bridging, antiplatelet management)
- Anticoagulation reversal — reversal pharmacology for bleeding or urgent surgery
- ERAS — enhanced-recovery context
- Post-op bowel & ileus management — alvimopan and early mobilization
References
1. Klaassen Z, Arora K, Goldberg H, et al. "Extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines." J Urol. 2018;199(4):906–914. doi:10.1016/j.juro.2017.08.130
2. VanDlac AA, Cowan NG, Chen Y, et al. "Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis." J Urol. 2014;191(4):943–947. doi:10.1016/j.juro.2013.10.096
3. Najdi J, Ayoub CH, Chawareb EA, et al. "Preoperative risk factors for venous thromboembolism in major urologic cancer surgeries." World J Urol. 2024;43(1):10. doi:10.1007/s00345-024-05372-9
4. Farge D, Frere C, Connors JM, et al. "2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19." Lancet Oncol. 2022;23(7):e334–e347. doi:10.1016/S1470-2045(22)00160-7
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease. Version 3.2025. Updated 2025-11-06.
6. Gould MK, Garcia DA, Wren SM, et al. "Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines." Chest. 2012;141(2 Suppl):e227S–e277S. doi:10.1378/chest.11-2297
7. Naik R, Mandal I, Hampson A, et al. "The role of extended venous thromboembolism prophylaxis for major urological cancer operations." BJU Int. 2019;124(6):935–944. doi:10.1111/bju.14906
8. Sun AJ, Djaladat H, Schuckman A, et al. "Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events." J Urol. 2015;193(2):565–569. doi:10.1016/j.juro.2014.08.085
9. Anderson DR, Morgano GP, Bennett C, et al. "American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients." Blood Adv. 2019;3(23):3898–3944. doi:10.1182/bloodadvances.2019000975
10. Lobastov K, Urbanek T, Stepanov E, et al. "The thresholds of Caprini score associated with increased risk of venous thromboembolism across different specialties: a systematic review." Ann Surg. 2023;277(6):929–937. doi:10.1097/SLA.0000000000005843
11. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. "Prevention of venous thromboembolism in gynecologic surgery: ACOG Practice Bulletin, Number 232." Obstet Gynecol. 2021;138(1):e1–e15. doi:10.1097/AOG.0000000000004445
12. Pannucci CJ, Swistun L, MacDonald JK, Henke PK, Brooke BS. "Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis." Ann Surg. 2017;265(6):1094–1103. doi:10.1097/SLA.0000000000002126
13. US Food and Drug Administration. Enoxaparin Sodium — prescribing information. Updated 2026-02-04.
14. US Food and Drug Administration. Enoxaparin Sodium — prescribing information. Updated 2025-09-30.
15. Farge D, Frere C, Connors JM, et al. "2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer." Lancet Oncol. 2019;20(10):e566–e581. doi:10.1016/S1470-2045(19)30336-5
16. Murphy PB, Vogt KN, Lau BD, et al. "Venous thromboembolism prevention in emergency general surgery: a review." JAMA Surg. 2018;153(5):479–486. doi:10.1001/jamasurg.2018.0015
17. Slinger M, Michel KF, Xia L, et al. "Perioperative use of venous thromboembolism prophylaxis following major urologic oncology surgeries: a survey of the Society of Urologic Oncology." Urol Oncol. 2025. doi:10.1016/j.urolonc.2025.10.020
18. US Food and Drug Administration. Eliquis (apixaban) — prescribing information. Orange Book.
19. Westerman ME, Bree KK, Msaouel P, et al. "Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study." J Urol. 2022;208(4):886–895. doi:10.1097/JU.0000000000002788
20. Kakkos S, Kirkilesis G, Caprini JA, et al. "Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism." Cochrane Database Syst Rev. 2022;1:CD005258. doi:10.1002/14651858.CD005258.pub4
21. Arabi YM, Al-Hameed F, Burns KEA, et al. "Adjunctive intermittent pneumatic compression for venous thromboprophylaxis." N Engl J Med. 2019;380(14):1305–1315. doi:10.1056/NEJMoa1816150
22. Falck-Ytter Y, Francis CW, Johanson NA, et al. "Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines." Chest. 2012;141(2 Suppl):e278S–e325S. doi:10.1378/chest.11-2404